Treatment of chemotherapy-induced thrombocytopenia in …
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment of non-hematologic malignancies. Many patient-related variables (e.g., age, tumor type, number of prior chemotherapy cycles, amount of bone marrow tumor involvement) determine the extent of …
Cisplatin - StatPearls - NCBI Bookshelf - National Center for ...
2023年5月22日 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. This activity reviews the indications, action, and contraindications for cisplatinum as a valuable agent in treating malignancy.
Management of chemotherapy-induced thrombocytopenia: …
Studies of treatment or prevention of CIT have focused on the correction of thrombocytopenia and ability to administer full-dose chemotherapy. Altering the dose and schedule of chemotherapy is the primary current option to reduce the risk and incidence of CIT, and platelet transfusions may be used during severe nadir.
Managing Thrombocytopenia Associated With Cancer …
2015年4月15日 · In another blinded, placebo-controlled study, patients with solid tumors and a platelet count ≤ 300,000/µL receiving either gemcitabine alone (14 patients) or gemcitabine plus either cisplatin or carboplatin (12 patients) were randomized to receive eltrombopag or placebo on days −5 to −1 and days 2 through 6, starting from cycle 2; no ...
Frontiers | Case Report: Life-threatening pancytopenia with ...
2023年7月24日 · Here, we present the case of a 66-year-old male patient with metastatic lung adenocarcinoma who received two doses of chemotherapy + PD-1 antibody tislelizumab and developed pancytopenia after each dose.
Hematologic Rescue of CAR T-cell–mediated Prolonged Pancytopenia …
2021年2月17日 · We report on a case of severe prolonged pancytopenia after CD19 CAR T-cell (CART) therapy for aggressive lymphoma that successfully resolved after autologous peripheral blood stem cell transplantation (ASCT). A 51-year-old female suffered from germinal center-type double-hit diffuse large B-cell lymphoma (DLBCL).
Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin …
2019年5月21日 · We present a case of a 33-year-old man with an early-onset stage IV intrahepatic cholangiocarcinoma, who experienced unusual bone marrow failure and neutropenic fever syndrome as a consequence of palliative chemotherapy containing cisplatin and gemcitabine, leading to a fatal outcome on day 25 of his first chemotherapeutic cycle.
Cisplatin | Reactions Weekly - Springer
2024年4月13日 · CT angiography revealed a thrombus of 2-mm in length in the middle third of the right middle cerebral artery. In the ICU, she developed chemotherapy-induced neutropenia and pancytopenia, which further complicated with respiratory septic shock and middle cerebral artery ischaemic stroke.
Cisplatin/gemcitabine : Pancytopenia: case report - Europe PMC
2021年1月1日 · A 54-year-old man developed pancytopenia during treatment with cisplatin and gemcitabine for nasopharyngeal carcinoma [routes and dosages not stated]. The man, who had nasopharyngeal carcinoma with lung and bone metastasis, presented to hospital with one day history of dyspnoea, anorexia and fever.
The side effects of platinum-based chemotherapy drugs: a review …
The dose-limiting side effect for cisplatin is nephrotoxicity, for carboplatin it is myelosuppression, and for oxaliplatin it is neurotoxicity. Other common side effects include anaphylaxis, cytopenias (including leukopenia and neutropenia, thrombocytopenia, and anaemia), hepatotoxicity, ototoxicity, cardiotoxicity, nausea and vomiting ...